TABLE 2

SPR analysis of TcdA and TcdB toxin fragments

Antigen or oligosaccharide Protein binding (KD)a
ToxA-B1ToxA-B3ToxB-B2
Blood group A1.53 μM ± 0.6 μM61.4 nM ± 29.6 nM29.1 nM ± 7.5 nM
Blood group B11.4 μM ± 1.08 μM14.4 μM ± 3.2 μM42.9 μM ± 59.1 μM
Blood group H1.22 μM ± 0.49 μMNCDI428 nM ± 8 nM
Lewis A3.38 μM ± 0.95 μM1.65 μM ± 0.62 μM579 nM ± 37 nM
Lewis B1.05 μM ± 0.63 μM8.01 μM ± 0.58 μM395 nM ± 29 nM
Lewis Y12.7 μM ± 2.47 μM55.5 μM ± 28.8 μM8 μM ± 0.74 μM
Lewis X18.9 μM ± 5.58 μM16.5 μM ± 2.8 μM501 nM ± 308 nM
Sialyl-Lewis A71.8 μM ± 27.1 μM72.1 μM ± 31.8 μM2.39 μM ± 0.68 μM
Sialyl-Lewis X91.1 μM ± 4.16 μM1.07 μM ± 0.15 μM34.7 μM ± 11.5 μM
2-6SLNNCDINCDI105 nM ± 8.45 nM
α-Methyl-mannoseNCDINCDI315 nM ± 103 nM
Man5bNCDINCDINCDI
  • a KD is reported ±1 standard deviation. ToxB-GT was also tested with no concentration-dependent interaction observed for all glycans. NCDI, no concentration-dependent interaction observed up to the maximum concentration tested (100 μM). For representative curves, see Fig. S2 in the supplemental material.

  • b Mannopentaose.